These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33193975)

  • 21. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors.
    Skrahina A; Hurevich H; Zalutskaya A; Sahalchyk E; Astrauko A; Hoffner S; Rusovich V; Dadu A; de Colombani P; Dara M; van Gemert W; Zignol M
    Bull World Health Organ; 2013 Jan; 91(1):36-45. PubMed ID: 23397349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the yield of tuberculosis among contacts of multidrug-resistant and drug-sensitive tuberculosis patients in Ethiopia using GeneXpert as a primary diagnostic test.
    Hiruy N; Melese M; Habte D; Jerene D; Gashu Z; Alem G; Jemal I; Tessema B; Belayneh B; Suarez PG
    Int J Infect Dis; 2018 Jun; 71():4-8. PubMed ID: 29559367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh.
    Rifat M; Hall J; Oldmeadow C; Husain A; Hinderaker SG; Milton AH
    BMJ Open; 2015 Sep; 5(9):e008273. PubMed ID: 26351185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study.
    Elduma AH; Mansournia MA; Foroushani AR; Ali HMH; Elegail AMA; Elsony A; Holakouie-Naieni K
    Epidemiol Health; 2019; 41():e2019014. PubMed ID: 31010280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia.
    Demile B; Zenebu A; Shewaye H; Xia S; Guadie A
    BMC Infect Dis; 2018 May; 18(1):249. PubMed ID: 29855354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for multidrug-resistant tuberculosis in Hong Kong.
    Law WS; Yew WW; Chiu Leung C; Kam KM; Tam CM; Chan CK; Leung CC
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1065-70. PubMed ID: 18713506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community.
    Andrews JR; Shah NS; Weissman D; Moll AP; Friedland G; Gandhi NR
    PLoS One; 2010 Dec; 5(12):e15735. PubMed ID: 21209951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study.
    Kizito E; Musaazi J; Mutesasira K; Twinomugisha F; Namwanje H; Kiyemba T; Freitas Lopez DB; Nicholas NS; Nkolo A; Birabwa E; Dejene S; Zawedde-Muyanja S
    BMC Infect Dis; 2021 Mar; 21(1):292. PubMed ID: 33752637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and Risk Factors of Primary Drug-Resistant Tuberculosis in China.
    Wang SF; Zhou Y; Pang Y; Zheng HW; Zhao YL
    Biomed Environ Sci; 2016 Feb; 29(2):91-8. PubMed ID: 27003166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and clinical predictors of drug-resistant tuberculosis in three clinical settings in Calabar, Nigeria.
    Otu A; Umoh V; Habib A; Ansa V
    Clin Respir J; 2014 Apr; 8(2):234-9. PubMed ID: 24131513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Multi-Drug Resistant
    Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
    Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. More than half of presumptive multidrug-resistant cases referred to a tuberculosis referral laboratory in the Tigray region of Ethiopia are multidrug resistant.
    Tesfay K; Tesfay S; Nigus E; Gebreyesus A; Gebreegziabiher D; Adane K
    Int J Mycobacteriol; 2016 Sep; 5(3):324-327. PubMed ID: 27847018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study.
    Iradukunda A; Ndayishimiye GP; Sinarinzi D; Odjidja EN; Ntakaburimvo N; Nshimirimana I; Izere C
    BMC Public Health; 2021 Nov; 21(1):2142. PubMed ID: 34814876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India.
    Sethi S; Mewara A; Dhatwalia SK; Singh H; Yadav R; Singh K; Gupta D; Wanchu A; Sharma M
    BMC Infect Dis; 2013 Mar; 13():137. PubMed ID: 23497169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa.
    Loveday M; Sunkari B; Master I; Daftary A; Mehlomakulu V; Hlangu S; Marais BJ
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):40-46. PubMed ID: 29297424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.